Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The mechanistic target of rapamycin (mTOR) protein kinase coordinates responses to nutrients and growth factors and is an anti-cancer drug target. To anticipate how cells will respond and adapt to chronic mTORC1 and mTORC2 inhibition we have generated SW620 colon cancer cells with acquired resistance to the ATP-competitive mTOR kinase inhibitor AZD8055 (SW620:8055R). AZD8055 inhibited mTORC1 and mTORC2 signalling and caused a switch from cap-dependent to IRES-dependent translation in parental SW620 cells. In contrast, SW620:8055R cells exhibited a loss of S6K signalling, an increase in expression of the eukaryotic translation initiation factor eIF4E and increased cap-dependent mRNA translation. As a result the expression of CCND1 and MCL1, proteins encoded by eIF4E-sensitive and capdependent transcripts, was refractory to AZD8055 in SW620:8055R cells. RNAimediated knockdown of eIF4E reversed acquired resistance to AZD8055 in SW620:8055R cells; furthermore increased expression of eIF4E was sufficient to reduce sensitivity to AZD8055 in a heterologous cell system. Finally, whilst the combination of MEK1/2 inhibitors with mTOR inhibitors is an attractive rational drug combination, SW620:8055R cells were actually cross-resistant to the MEK1/2 inhibitor selumetinib. These results exemplify the convergence of ERK1/2 and mTOR signalling at eIF4E and the key role of eIF4E downstream of mTOR in maintaining cell proliferation. They also have important implications for therapeutic strategies based around mTOR and MEK1/2-ERK1/2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Thoreen, C. C., Kang, S. A., Chang, J. W., Liu, Q., Zhang, J., Gao, Y., Reichling, L. J., Sim, T., Sabatini, D. M., & Gray, N. S. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m900301200 · Cited by 1,803
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity
Um, S. H., Frigerio, F., Watanabe, M., Picard, F., Joaquin, M., Sticker, M., Fumagalli, S., Allegrini, P. R., Kozma, S. C., Auwerx, J., et al. (2004) · Nature · doi:10.1038/nature02866 · Cited by 1,677
Dissecting eIF4E action in tumorigenesis
Wendel, H.-G., Silva, R. L. A., Malina, A., Mills, J. R., Zhu, H., Ueda, T., Watanabe-Fukunaga, R., Fukunaga, R., Teruya-Feldstein, J., Pelletier, J., et al. (2007) · Genes & Development · doi:10.1101/gad.1604407 · Cited by 487 · cited 2×
“, 2010), and active eIF4E is required for the transforming effects of PKB on mRNA translation, cell growth, tumour formation and maintenance (Wendel et al., 2007).”
BackgroundShe, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400 · cited 1×
“contrast, S6K makes a more modest contribution to the oncogenic action of ERK1/2 or PKB compared to the 4EBP–eIF4E pathway (Hsieh et al., 2010; She et al., 2010).”
BackgroundTzatsos, A., & Kandror, K. V. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.63-76.2006 · Cited by 399
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194 · cited 1×
“We also examined the expression of CCND1 and MCL1, two proteins whose mRNAs are eIF4Esensitive and translated in a cap-dependent fashion (Tan et al., 2000; Wendel et al., 2007; Averous et al., 2008).”
Background
Cited by
Targeting mTOR for cancer therapy
Hua, H., Kong, Q., Zhang, H., Wang, J., Luo, T., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 899
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
mTOR coordinates protein synthesis, mitochondrial activity and proliferation
Morita, M., Gravel, S.-P., Hulea, L., Larsson, O., Pollak, M., St-Pierre, J., & Topisirovic, I. (2015) · Cell Cycle · doi:10.4161/15384101.2014.991572 · Cited by 552
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
“Elevated eIF4E levels are also associated with resistance to PI3K/mTOR kinase inhibitors (150, 151).”
BackgroundTranslational Control in Cancer
Robichaud, N., Sonenberg, N., Ruggero, D., & Schneider, R. J. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032896 · Cited by 302
Metadata
- Authors
- Cope, C. L., Gilley, R., Balmanno, K., Sale, M. J., Howarth, K. D., Hampson, M., Smith, P. D., Guichard, S. M., & Cook, S. J.
- Venue
- Journal of Cell Science
- Publisher
- The Company of Biologists
- Published
- 2013-01-01
- Volume
- 127
- Issue
- Pt 4
- Pages
- 788-800
- ISSN
- 0021-9533 (ISSN-L)
- 1477-9137
- OpenAlex
- W2116761906
- Cited by
- 79
- References
- 7
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. https://app.cochat.ai/papers/10.1242/jcs.137588
- The paper
- Cope, C. L., Gilley, R., Balmanno, K., Sale, M. J., Howarth, K. D., Hampson, M., Smith, P. D., Guichard, S. M., & Cook, S. J. (2013). Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. Journal of Cell Science. https://doi.org/10.1242/jcs.137588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.